29 Jul 2026
Fact.MR sizes the GLP-1 patient support market at $545.0 Mn in 2026, rising to $2850 Mn by 2036: an 18.0% CAGR, $2310 Mn of absolute opportunity. Onboarding is where GLP-1 therapy most often stalls, because getting patients started, trained, and covered is the hard part. Onboarding and injection training leads program components at 37.9%, digital-first hubs lead delivery at 34.7%, and pharma manufacturers sponsor 54.5% of the market. The USA (17.5%), Germany (17.1%), and France (16.8%) grow fastest.
For brand teams, patient support has become the make-or-break layer around a launch. The focus has moved to onboarding and injection training, because the first few weeks decide persistence. Digital-first hubs are preferred for their reach across large patient populations, and copay and access support is built in to take the edge off affordability friction. The specification now runs from prescription all the way to persistence, not a single helpline.
Onboarding and injection training leads program components at 37.9%, the moment that most shapes whether a patient continues. Digital-first hubs lead delivery at 34.7%. Pharma manufacturers are both the dominant sponsor (54.5%) and 43.3% of end users, which governs how these programs are designed and policed. Copay and access support, persistence outreach, outcomes reporting, and a side-effect helpline round out the components: manufacturer-funded, digitally delivered, built around onboarding.
The USA leads at 17.5%, followed by Germany (17.1%), France (16.8%), the UK (16.5%), and Japan (16.0%). Growth follows launch activity and the scale of manufacturer support programs. The full report carries the country-level read into East Asia and South Asia and Oceania, placing China and India within the wider comparison. The USA moves fastest given its market size and hub-based model.
Fragmentation is the recurring complaint, as disjointed components dilute the patient experience. Promotional-compliance risk sits heavily on manufacturer-run support, where the line between help and marketing gets watched closely. And attribution is difficult, so proving a program moved persistence is not straightforward. The pull, then, is toward integrated, well-governed programs.
EVERSANA, CareMetx, Valeris, CoverMyMeds, Phil, and AssistRx are assembling integrated hub and access services around GLP-1 brands. Several fold onboarding, copay support, and persistence outreach into one digital-first program. The emphasis is on compliant, measurable support a manufacturer can stand behind, with access and reimbursement tooling prominent in the offering.
Judge how well a program unifies onboarding, access, and persistence instead of stitching parts together. Check the promotional-compliance safeguards, since manufacturer support attracts scrutiny. Keep outcome attribution in view so value can be shown, and watch whether digital-first hubs scale without losing the personal touch onboarding needs. US launch activity paces the category.
Segmentation runs by program component, sponsor type, delivery mode, end user, and region, with country-level growth compared across North America, Europe, Asia Pacific, Central and South America, and the Middle East amp Africa from 2026 to 2036. The analysis serves pharma brand teams, hub-service providers, and payers evaluating patient support, and combines segment shares, country CAGRs, and a driver-restraint view.
Expert analysis, actionable insights, and strategic recommendations of the highly seasoned healthcare team at Fact.MR helps clients from across the globe with their unique business intelligence needs. With a repertoire of over a thousand reports and 1 million-plus data points, the team has analyzed the healthcare industry across 50+ countries for over a decade. The team provides unmatched end-to-end research and consulting services. Reach out to explore how we can help.
For more information, refer to our market research report or contact the PR author.
GLP-1 Patient Support Market
Free SampleAbout Fact.MR
Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. We are known for our syndicated research, custom research, and consulting solutions.